Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.
1. A compound of Formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof:
wherein
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, 3, 4, or 5;
p is 0, 1, or 2;
q is 0, 1, 2, 3, or 4;
t is 0, 1, 2, 3, 4, or 5;
X is —CO— or —SO 2 —;
Y is selected from the group consisting of:
(1) C 1 -C 5 alkanediyl, C 2 -C 5 alkenediyl, and C 2 -C 5 alkynediyl, wherein each of alkanediyl, alkenediyl and alkynediyl is optionally substituted with one to three groups independently selected from halogen, —OR a , —S(O) p —C 1 -C 3 alkyl;
(2) —(CR a R a ) j -Q-(CR a R a ) k , wherein j and k are integers independently selected from 0, 1 and 2,
(3) a bond, and
(4) phenylene optionally substituted with one to three groups independently selected from R 1 ;
Z is selected from the group consisting of:
(2) a 5- or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen;
R 1 is selected from the group consisting of:
(1) C 1 -C 5 alkyl optionally substituted with 1 to 5 halogen atoms,
(2) C 3 -C 6 cycloalkyl,
(3) halogen,
(4) nitro,
(5) cyano,
(6) —C(O)R a ,
(7) —C(O) 2 R a ,
(8) —C(O)NR a R b , and
(9) -QR b ;
R 2 is selected from the group consisting of halogen and C 1 -C 5 alkyl;
R 3 is selected from the group consisting of:
(1) C 1 -C 6 alkyl optionally substituted with 1 to 5 groups independently selected from halogen, —OR a , —CO 2 R a , and —CONR a R b ,
(2) —(CH 2 ) t -phenyl or —(CH 2 ) t —O-phenyl, and wherein said phenyl in each is optionally substituted with 1 to 3 groups independently selected from halogen, C 1 -C 5 alkyl optionally substituted with 1 to 5 halogen atoms, and —OR a ,
(3) oxo,
(4) thioxo,
(5) halogen,
(6) —CN,
(7) C 3 -C 6 cycloalkyl,
(8) —(CH 2 ) t -heterocyclic ring or —(CH 2 ) t —O-heterocyclic ring, and wherein the heterocyclic ring in each is a 5- or 6-membered ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, and wherein said heterocyclic ring is optionally ortho-fused to a benzene ring, and optionally substituted with 1 to 3 groups independently selected from halogen, C 1 -C 5 alkyl optionally substituted with 1 to 5 halogen atoms, and —OR a ,
(9) —OR a ,
(10) —C(O)OR a ,
(11) —C(O)R a ,
(12) —C(O)NR a R b ,
(12) —NR a R b ,
(13) —NR a C(O)R b ,
(14) —NR a C(O)OR b , and
(15) —NR a C(O)NR a R b ;
R a is selected from the group consisting of hydrogen and C 1 -C 6 alkyl optionally substituted with 1 to 5 halogen atoms;
R b is selected from the group consisting of:
(1) hydrogen,
(2) C 1 -C 6 alkyl optionally substituted with 1 to 5 groups selected from the group consisting of:
(a) hydroxy,
(b) halogen,
(c) —CO 2 R a ,
(d) —S(O) p —C 1 -C 3 alkyl;
(e) C 3 -C 8 cycloalkyl,
(f) C 1 -C 6 alkoxy optionally substituted with 1 to 5 halogens, and
(g) phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of halogen, nitro, —NR a R a , R a , trifluoromethyl, trifluoromethoxy, C 1 -C 5 alkyl and —OR a ,
(3) C 3 -C 8 cycloalkyl, and
(4) phenyl optionally substituted with 1 to 5 groups selected from the group consisting of:
(a) halogen,
(b) nitro,
(c) —NR a R a ,
(d) —OH,
(e) C 1 -C 6 alkoxy optionally substituted with 1 to 5 halogens,
(f) —S(O) p —C 1 -C 6 alkyl; and
(g) C 1 -C 6 alkyl optionally substituted with up to 5 groups selected from hydroxy, halogen, trifluoromethyl, cyano, —CO 2 R a , C 3 -C 8 cycloalkyl, and -QR c ; R c is selected from the group consisting of:
(1) Z optionally substituted with up to 5 groups selected from halogen, trifluoromethyl, cyano, C 1 -C 5 alkyl and C 1 -C 5 alkoxy, and
(2) C 1 -C 6 alkyl; and
Q is selected from the group consisting of:
(1) —N(R a )—,
(2) —O—, and
(3) —S(O) p —.
2. The compound of claim 1 having Formula Ia, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof:
wherein Y, Z, R 3 and n are as defined in claim 1 .
3. The compound of claim 2 wherein Y is methylene, —CH(CH 3 )— or a bond.
4. The compound of claim 2 wherein Z is selected from the group consisting of thiazolyl, oxazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, pyrrolidinyl, imidazolyl, pyrazolyl, 1,2,4-oxadiazolyl, and 1,2,5-oxadiazolyl.
5. The compound of claim 2 wherein R 3 is selected from the group consisting of:
(1) C 1 -C 6 alkyl optionally substituted with halogen or —OR a ,
(2) oxo,
(3) halogen,
(4) —OR a ,
(5) —C(O)NR a R a , and
(6) —NR a R a ;
wherein R a is as defined in claim 2 .
6. A compound of Formula Ia, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof:
wherein
n is 0, 1 or 2;
Y is selected from the group consisting of methylene, —CH(CH 3 )— and a bond;
Z is selected from the group consisting of thiazolyl, 1,2,4-triazolyl, and pyrazolyl; and
R 3 is selected from the group consisting of:
(1) methyl,
(2) oxo, and
(3) —NH 2 .
7. The compound of claim 6 ,
wherein n is 1;
Y is —CH(CH 3 )—;
Z is 1,2,4-triazolyl; and
R 3 is methyl.
8. A compound of claim 1 selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof.
9. A compound of claim 8 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof.
10. A compound of claim 9 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof.
11. A compound of claim 10 , wherein the compound is:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof.
12. A compound of claim 10 , wherein the compound is:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof.
13. A compound of claim 9 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof.
14. A compound of claim 13 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof.
15. A compound of claim 13 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable stereoisomer thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof.
16. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
17. A method for the treatment or prevention of a disease or disorder mediated by the activation of β3-adrenoceptor, wherein said method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 .
18. The method of claim 17 wherein the disease or disorder is selected from the group consisting of (1) overactive bladder, (2) urinary incontinence, (3) urge urinary incontinence, and (4) urinary urgency.
19. A method for the treatment or prevention of a disease or disorder mediated by the activation of β3-adrenoceptor, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 and a second active agent.
20. The method of claim 19 , wherein the second active agent is a muscarinic receptor antagonist.